Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEROTOX: Botulinum toxin for degenerative rotator cuff tendinopathy
2021-003315-25Phase 2Active
- Start
- Jan 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of botulinum toxin type A in rotator cuff degeneration (RCT) and shoulder tendinopathy (2 arms). Primary endpoint: Total SPADI score at 1 month. Started Jan 2022; status: active.
02
Drugs
botulinum toxin type A
03
Conditions
rotator cuff degeneration (RCT)shoulder tendinopathy
Beyond the preview
Go deeper on 2021-003315-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003315-25.